Results 271 to 280 of about 326,443 (336)

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, EarlyView.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study. [PDF]

Front Immunol
He S, Wang C, Li X, Li C, Li D, Zhang B, Wan J, Yue Z, Wu G, Zhang S, Ma J, Shang P.   +11 more
europepmc   +1 more source

Therapeutic targeting in HER2+ breast cancer to prevent and treat CNS disease: CDC20.

Mamoor, Shahan
openalex   +1 more source

The Contribution of Cholesterol and Squalene Synthase in Cancer: Molecular Mechanisms, Lipid Rafts and Therapeutic Approaches

Medicinal Research Reviews, EarlyView.
ABSTRACT A plethora of cellular signaling pathways are dysregulated in cancer cells, promoting carcinogenesis and migration. Cholesterol has recently been linked to cancer by several subcellular mechanisms, especially by its involvement in the formation of lipid rafts, which promote oncogenic signaling and cancer cell invasion. Squalene synthase (SQS),
Danai Mavridi, Theodora Katavati, Angeliki P. Kourounakis   +2 more
wiley   +1 more source

Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China. [PDF]

PeerJ
Zhi L, Huang L, Pang X, Wu Q, Lei Y.
europepmc   +1 more source

HER2 Inhibitor [PDF]

, 2020
openaire   +1 more source

Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary of the DESTINY-CRC02 study. [PDF]

Future Oncol
Raghav K.
europepmc   +1 more source

Human Epidermal Growth Factor Receptor Type 2 (HER2)-Positive Metastatic Breast Cancer With HER2-Negative Conversion: A Case Report and Treatment With Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor for the Luminal Type [PDF]

Ryo Funakushi, Sayaka Kuba, Michi Morita, Momoko Akashi, Susumu Eguchi   +4 more
openalex   +1 more source

Synthesis of 1,2,3,4‐Tetrahydroisoquinoline‐3‐Carboxylic Acid‐Embedded Decapeptides: In Silico Studies and In Vitro Evaluation Against Breast Cancer

ChemistryOpen, EarlyView.
Synthesized decapeptides were designed and validated by in silico studies. They have significantly exhibited anticancer potential against breast cancer and MCF‐7 cell line. The above illustration specifies the synthetic pathway, biological screening, and the mode of action of the peptide in blocking the pathways responsible for the growth of cancer ...
Sunil Tivari, Naurin Lalani, Pritam Bagwe, Prashant Chandole, Ramesh Pawar, Enrique Delgado‐Alvarado, Abdallah Othman Ghnaim, Yashwantsinh Jadeja   +7 more
wiley   +1 more source